Corticosteroids are highly effective in inducing clinical remission in patients with active Crohn’s
disease. However, the role of corticosteroids in the treatment of this disease is primarily …

Background Studies in animals and an open-label trial have suggested a role for antibodies
to tumor necrosis factor α, specifically chimeric monoclonal antibody cA2, in the treatment of …

Background: The aim of the present study was to develop a breath test for measuring gastric
emptying rate of solids that would induce less radiation exposure than radioscintigraphy …

Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab
induction therapy in patients with Crohn’s disease. Methods: Patients (N = 509) with …

… Paul Rutgeerts has served as a speaker for Centocor, Schering-Plough, UCB, Abbott,
Elan-Biogen, a consultant for Centocor, Schering-Plough, UCB, Abbott, Elan-Biogen, NovImmune, …

Background & Aims: Anti–tumor necrosis factor α monoclonal antibody treatment (infliximab)
reduces clinical signs and symptoms in patients with Crohn's disease. The effects of …

We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind,
placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory …

The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory
and biologic therapies has led to more demanding endpoints for clinical trials than …

BACKGROUND & AIMS: We determined the effects of adalimumab maintenance treatment
on the risks of hospitalization and surgery in Crohn's disease (CD). METHODS: A total of 778 …

Objective Although low infliximab trough concentrations and antibodies to infliximab (ATI)
are associated with poor outcomes in patients with Crohn's disease (CD), the clinical …